Patents by Inventor Gerald A. Beltz
Gerald A. Beltz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8461323Abstract: The present invention relates, in general, to polypeptides having antigenic epitopes from granulocytic ehrlichia (GE) proteins and methods of use thereof.Type: GrantFiled: January 9, 2012Date of Patent: June 11, 2013Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 8435495Abstract: The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection.Type: GrantFiled: June 25, 2012Date of Patent: May 7, 2013Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20120270232Abstract: The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection.Type: ApplicationFiled: June 25, 2012Publication date: October 25, 2012Applicant: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20120178102Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S1, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: ApplicationFiled: January 9, 2012Publication date: July 12, 2012Applicant: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 8093008Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: GrantFiled: August 18, 2010Date of Patent: January 10, 2012Assignee: Antigenics, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 7863434Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: GrantFiled: February 26, 2001Date of Patent: January 4, 2011Assignee: Antigenics Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20100088774Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: ApplicationFiled: February 26, 2001Publication date: April 8, 2010Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Publication number: 20050191310Abstract: Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.Type: ApplicationFiled: October 3, 2003Publication date: September 1, 2005Inventors: Charlotte Kensil, Gerald Beltz
-
Patent number: 6645495Abstract: Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.Type: GrantFiled: August 28, 1998Date of Patent: November 11, 2003Assignee: Antigenics, Inc.Inventors: Charlotte A. Kensil, Gerald A. Beltz
-
Publication number: 20020044951Abstract: Nonpeptide antigens were isolated and purified from Mycobacterium tuberculosis. The antigens were used in vaccine compositions, pharmaceutical compositions and methods to elicit an immune response to Mycobacterium tuberculosis in a mammal.Type: ApplicationFiled: April 4, 2001Publication date: April 18, 2002Inventors: Gui Liu, Gerald Beltz, Kenneth LeClair, Daniel Cox, Charlotte Kensil
-
Patent number: 6306394Abstract: Nucleic acids encoding eleven different proteins of granulocytic erhlichia (GE), a tick-borne intracellular bacteria, have been isolated and sequenced completely. These DNAs were isolated as immunoreactive clones from a Lambda Zap II genomic library of GE DNA purified from infected HL60 cells. Three of the clones, E8, E80, and E46, contain open reading frames for four highly homologous proteins which appear to be part of a multigene family resembling the MSP-2 gene family of Anaplasma marginale. One clone, B3, contained a gene encoding the heat shock 70 protein. The other clones (W20, E74, and E82) contain open reading frames for proteins which have some homology to other bacterial proteins present in the nucleotide and protein databases. These and other GE antigens identified by immunoscreening of the genomic library are potentially useful as diagnostic reagents and vaccine candidates for GE.Type: GrantFiled: April 24, 1998Date of Patent: October 23, 2001Assignee: Aquila Biopharmaceuticals Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 6228608Abstract: Feline immunodeficiency virus antigens from gp160 envelope protein, gp120 envelope protein and p24 gag protein, useful for the diagnosis, treatment, and prevention of FIV. The invention may also be used to purify FIV.Type: GrantFiled: February 28, 1991Date of Patent: May 8, 2001Assignee: Aquila Biopharmaceuticals, Inc.Inventors: Eli Young, Deborah Davis, James Storey, Gerald Beltz
-
Patent number: 6204252Abstract: The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.Type: GrantFiled: April 24, 1998Date of Patent: March 20, 2001Assignee: Aquila Biopharmaceuticals, Inc.Inventors: Cheryl Murphy, James Storey, Gerald A. Beltz, Richard T. Coughlin
-
Patent number: 5352449Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.Type: GrantFiled: April 14, 1992Date of Patent: October 4, 1994Assignee: Cambridge Biotech CorporationInventors: Gerald A. Beltz, Dante J. Marciani, Chung-Ho Hung, Charlotte A. Kensil
-
Patent number: 4753873Abstract: Certain peptide fragments of the human T-cell leukemia (lymphotropic) virus (HTLV-III) are particularly immunoreactive to HTLV-III antibodies, and can therefore be applied to immunodiagnostic tests for the detection of antibodies to HTLV-III.Type: GrantFiled: February 3, 1986Date of Patent: June 28, 1988Assignee: Cambridge Bioscience CorporationInventors: Gerald A. Beltz, Richard M. Thorn, Dante J. Marciani, Chung-Ho Hung, William A. Haseltine